High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.
A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.
McMurtry
S A
SA
Division of Allergy, Children's Memorial Hospital, Chicago, Illinois, USA.
Nimmagadda
S R
SR
D000280:Administration, Inhalation; D000284:Administration, Oral; D000293:Adolescent; D000730:Androstadienes / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002641:Chicago; D002648:Child; D002669:Child Welfare; D004305:Dose-Response Relationship, Drug; D005260:Female; D000068298:Fluticasone; D005500:Follow-Up Studies; D005540:Forced Expiratory Flow Rates / Q000187:drug effects; D005541:Forced Expiratory Volume / Q000187:drug effects*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D008297:Male; D010343:Patient Admission; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D012720:Severity of Illness Index; D019966:Substance-Related Disorders; D013997:Time Factors
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D000068298:Fluticasone